Insmed reports first-quarter 2024 financial results and provides business update

— arikayce® (amikacin liposome inhalation suspension) total revenue of $75.5 million for the first quarter of 2024, reflecting 16% annual growth over the first quarter of 2023— —company reports positive topline safety and tolerability data from the phase 2 ph-ild study of tpip with 79.3% of patients reaching the maximum dose of 640 Μg by week 5, with an unexpectedly positive and robust signal on the exploratory endpoint of clinical worsening— —encouraging blinded data from first 40 patients in phase 2 pah study of tpip, with combined active treatment and placebo arms showing mean pvr reduction of 19.9% and 6-minute walk distance improvement of 43 meters— —topline data from the phase 3 aspen trial of brensocatib in patients with bronchiectasis remains on track to read out in the latter part of second-quarter 2024— —company reiterates 2024 global arikayce revenue guidance in the range of $340 million to $360 million, reflecting double-digit growth compared to 2023— bridgewater, n.j. , may 9, 2024 /prnewswire/ -- insmed incorporated (nasdaq:insm), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the first quarter ended march 31, 2024 and provided a business update.
INSM Ratings Summary
INSM Quant Ranking